PRISMAFLEX SYSTEM, VERSION 3.20— 510(k) K072093
Substantially EquivalentGambro
FDA 510(k) clearance K072093 for PRISMAFLEX SYSTEM, VERSION 3.20, Substantially Equivalent on 2008-02-01. Applicant: Gambro. Device class: 2.
Clearance details
- Applicant
- Gambro
- Product code
- Code KDI
- Device class
- Class 2
- Regulation
- 21 CFR 876.5860
- Advisory panel
- Gastroenterology, Urology
- Date received
- Decision date
- Decision
- Substantially Equivalent
- Clearance type
- Traditional
- Location
- Lakewood, CO, US
Recent devices under product code KDI
view allAdverse events under product code KDI
product code KDI- Death
- 352
- Injury
- 1,474
- Malfunction
- 12,534
- Other
- 4
- Total
- 14,364
Source: openFDA MAUDE database, through . Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →
Recalls naming K072093
K-number listed on FDA's recall record- Z-1277-2021 — Prismaflex Control Unit - Product Usage: Used for Continuous Renal Replacement Therapy (CRRT).
- Z-1828-2020 — Prismaflex System, Prismaflex Control Unit
- Z-1829-2020 — Prismaflex System, Prismaflex Control Unit
- Z-1830-2020 — Prismaflex System, Prismaflex Control Unit
- Z-1831-2020 — Prismaflex System, Prismaflex Control Unit
- Z-1832-2020 — Prismaflex System, Prismaflex Control Unit
- Z-1833-2020 — Prismaflex System, Prismaflex Control Unit
- Z-0276-2020 — Prismaflex Control Unit, software versions below 7.21
- Z-0277-2020 — Prismaflex Control Unit, software versions below 7.21
- Z-0278-2020 — Prismaflex Control Unit, software versions below 7.21
- Z-0279-2020 — Prismaflex Control Unit, software versions below 7.21
- Z-0280-2020 — Prismaflex Control Unit, software versions below 7.21
- Z-1922-2018 — Prismaflex System, Product Code 107493 Intended Use: The Prismaflex Control Unit is intended for: " Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload. " Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where removal of plasma components is indicated. " Continuous Renal Replacement Therapy (CRRT) in conjunction with the MARS system to conduct MARS treatments for patients weighing 20 kilograms or more. All treatments administered via the Prismaflex control unit must be prescribed by a physician.
Matched by K-number from FDA's Recall Enterprise System record (openFDA device/recallk_numbers) — these recalls explicitly list K072093.
Data sourced from openFDA. This site is unofficial and independent of the FDA.